Who are Metvix and conventional PDT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Verteporfin for injection, Verteporfin Photodynamic Therapy, Methyl Aminolaevulinate 16% Cream, verteporfin PDT, MAL, Levulan® Kerastick®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metvix-and-conventional-pdt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metvix and conventional PDT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metvix and conventional PDT (Metvix and conventional PDT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photosensitizing agent. Area: Oncology / Dermatology.

phase 3 Photosensitizing agent Protoporphyrin IX (via aminolevulinic acid pathway) Oncology / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Metvix and conventional PDT (Metvix and conventional PDT) — Galderma R&D. Metvix is a photosensitizing agent that accumulates in abnormal skin cells and, when activated by light in photodynamic therapy (PDT), generates reactive oxygen species to destroy lesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Metvix and conventional PDT TARGET	Metvix and conventional PDT	Galderma R&D	phase 3	Photosensitizing agent	Protoporphyrin IX (via aminolevulinic acid pathway)
Verteporfin for injection	Verteporfin for injection	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Verteporfin Photodynamic Therapy	Verteporfin Photodynamic Therapy	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Methyl Aminolaevulinate 16% Cream	Methyl Aminolaevulinate 16% Cream	Galderma R&D	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolaevulinic acid pathway)
verteporfin PDT	verteporfin PDT	QLT Inc.	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
MAL	MAL	Photocure	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolevulinic acid pathway)
Levulan® Kerastick®	Levulan® Kerastick®	Medical Dermatology Specialists	marketed	Photosensitizing agent	Protoporphyrin IX (photodynamic therapy precursor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photosensitizing agent class)

Galderma R&D · 4 drugs in this class
Novartis · 2 drugs in this class
QLT Inc. · 2 drugs in this class
Medical Dermatology Specialists · 1 drug in this class
Photocure · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metvix and conventional PDT — Competitive Intelligence Brief. https://druglandscape.com/ci/metvix-and-conventional-pdt. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab